Glycosphingolipid-associated β-1,4 galactosyltransferase is elevated in patients with systemic lupus erythematosus

Objectiveβ-1,4 galactosyltransferase-V (β-1,4 GalT-V) is an enzyme that synthesises a glycosphingolipid known as lactosylceramide, which has been implicated in general inflammation and atherosclerosis. We asked if β-1,4 GalT-V was present at elevated levels in patients with SLE, a disease which is a...

Full description

Saved in:
Bibliographic Details
Published in:Lupus science & medicine 2020-07, Vol.7 (1), p.e000368
Main Authors: Sadras, Vignesh, Petri, Michelle A, Jones, Steven Richard, Peterlin, Barbara Lee, Chatterjee, Subroto
Format: Article
Language:English
Subjects:
Adult
Age
Antibodies
Antibodies, Antiphospholipid - blood
Atherosclerosis
Atherosclerosis - blood
Atherosclerosis - enzymology
Baltimore - epidemiology
Binding sites
Biomarker Studies
Blood pressure
Cardiovascular disease
Case-Control Studies
Cell adhesion & migration
Cholesterol
Diabetes
Enzyme-Linked Immunosorbent Assay - methods
Ethnicity
Female
Galactosyltransferases - metabolism
Heart attacks
Humans
Inflammation
Lactosylceramides - metabolism
Lipids
Lipoprotein(a) - blood
Lipoproteins
Lupus
Lupus Erythematosus, Systemic - blood
Lupus Erythematosus, Systemic - diagnosis
Lupus Erythematosus, Systemic - enzymology
Lupus Erythematosus, Systemic - ethnology
Male
Middle Aged
Neutrophils
Peptides
Phosphatase
Risk Factors
Signal transduction
Tumor necrosis factor-TNF
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objectiveβ-1,4 galactosyltransferase-V (β-1,4 GalT-V) is an enzyme that synthesises a glycosphingolipid known as lactosylceramide, which has been implicated in general inflammation and atherosclerosis. We asked if β-1,4 GalT-V was present at elevated levels in patients with SLE, a disease which is associated with increased risk of atherosclerosis.MethodsIn this case–control observational study, serum samples were obtained from patients with SLE who are part of the Johns Hopkins Lupus Cohort. Control serum samples were obtained from healthy adult community members recruited from the Baltimore area. All serum samples (n=50 in the SLE group and n=50 in the healthy control group) were analysed with enzyme-linked immunoassays. These assays used antibodies raised against antigens that enabled us to measure the absorbance of oxidised phosphocholines per apolipoprotein B-100 (ox-PC/apoB) and the concentration of lipoprotein(a) (Lp(a)) and β-1,4 GalT-V.ResultsAbsorbance of ox-PC/apoB and concentrations of Lp(a) and β-1,4 GalT-V were significantly higher in the SLE serum samples as compared with the control serum (p
ISSN:2053-8790
2053-8790
DOI:10.1136/lupus-2019-000368